The acute effect of budesonide/formoterol in COPD: a multi-slice computed tomography and lung function study

被引:48
作者
De Backer, Lieve A. [1 ]
Vos, Wim [2 ]
De Backer, Jan [2 ]
Van Holsbeke, Cedric [2 ]
Vinchurkar, Samir [2 ]
De Backer, Wilfried [1 ]
机构
[1] Univ Antwerp Hosp, Dept Resp Med, B-2650 Antwerp, Belgium
[2] FluidDA, Antwerp, Belgium
关键词
Chronic obstructive pulmonary disease; imaging techniques in chronic obstructive pulmonary disease; inhalation treatment; lung function testing; OBSTRUCTIVE PULMONARY-DISEASE; COMPUTATIONAL FLUID-DYNAMICS; FLUTICASONE PROPIONATE; HEALTH-STATUS; TRIAL; FLOW; SALMETEROL; MORTALITY; AIRWAYS; MODELS;
D O I
10.1183/09031936.00072511
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification of chronic obstructive pulmonary disease (COPD) does not always match with other clinical disease descriptors such as exacerbation frequency and quality of life, indicating that forced expiratory volume in 1 s (FEV1) is not a perfect descriptor of the disease. The aim of this study was to find out whether changes in airway geometry after inhalation of the most commonly used inhalation therapy in severe COPD can more adequately be described with an image-based approach than with spirometry. 10 COPD GOLD stage III patients were assessed in a double-blind crossover study. Airway volumes were analysed using segmentation of multi-slice computed tomography (MSCT) images; airway resistance was determined using computational fluid dynamics (CFD). Distal airway volume significantly increased (p=0.011) in patients 4 h after receiving a budesonide/formoterol combination from 9.6+/-4.67 cm(3) to 10.14+/-4.81 cm(3). Also CFD-determined airway resistance significantly decreased (p=0.047) from 0.051+/-0.021 kPa.s.L-1 to 0.043+/- 0.019 kPa.s.L-1. None of the lung function parameters showed a significant change. Only functional residual capacity (FRC) showed a trend to decline (p=0.056). Only the image-based parameters were able to predict the visit at which the combination product was administered. This study showed that imaging is a sensitive, complementary tool to describe changes in airway structure.
引用
收藏
页码:298 / 305
页数:8
相关论文
共 28 条
[1]   SPENDING ON NEW DRUG DEVELOPMENT [J].
Adams, Christopher Paul ;
Brantner, Van Vu .
HEALTH ECONOMICS, 2010, 19 (02) :130-141
[2]   Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease [J].
Appleton, S. ;
Poole, P. ;
Smith, B. ;
Veale, A. ;
Lasserson, T. J. ;
Chan, M. M. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (03)
[3]   Long-term mortality follow-up of the ISOLDE participants: Causes of death during 13 years after trial completion [J].
Bale, Geraldine ;
Martinez-Camblor, Pablo ;
Burge, P. Sherwood ;
Soriano, Joan B. .
RESPIRATORY MEDICINE, 2008, 102 (10) :1468-1472
[4]   Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J].
Burge, PS ;
Calverley, PMA ;
Jones, PW ;
Spencer, S ;
Anderson, JA ;
Maslen, TK .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245) :1297-1303
[5]   Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial [J].
Calverley, P ;
Pauwels, R ;
Vestbo, J ;
Jones, P ;
Pride, N ;
Gulsvik, A ;
Anderson, J ;
Maden, C .
LANCET, 2003, 361 (9356) :449-456
[6]   Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].
Calverley, Peter M. A. ;
Anderson, Julie A. ;
Celli, Bartolome ;
Ferguson, Gary T. ;
Jenkins, Christine ;
Jones, Paul W. ;
Yates, Julie C. ;
Vestbo, Jorgen ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Knobil, K. ;
Yates, J. C. ;
Vestbo, J. ;
Cherniack, R. ;
Similowski, T. ;
Cleland, J. ;
Whitehead, A. ;
Wise, R. ;
McGarvey, L. ;
John, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789
[7]   Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials [J].
Calverley, Peter M. A. ;
Rabe, Klaus F. ;
Goehring, Udo-Michael ;
Kristiansen, Soren ;
Fabbri, Leonardo M. ;
Martinez, Fernando J. .
LANCET, 2009, 374 (9691) :685-694
[8]   Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology [J].
Calverley, PMA ;
Koulouris, NG .
EUROPEAN RESPIRATORY JOURNAL, 2005, 25 (01) :186-199
[9]   Bronchodilator reversibility testing in chronic obstructive pulmonary disease [J].
Calverley, PMA ;
Burge, PS ;
Spencer, S ;
Anderson, JA ;
Jones, PW .
THORAX, 2003, 58 (08) :659-664
[10]   Flow analyses in the lower airways:: Patient-specific model and boundary conditions [J].
De Backer, J. W. ;
Vos, W. G. ;
Gorle, C. D. ;
Germonpre, P. ;
Partoens, B. ;
Wuyts, F. L. ;
Parizel, P. M. ;
De Backer, W. .
MEDICAL ENGINEERING & PHYSICS, 2008, 30 (07) :872-879